Engineering of bacterial strains and vectors for the production of plasmid DNA
Author(s)
Prather, Kristala L. Jones; Bower, Diana Morgan
DownloadPrather_Engineering of bacterial.pdf (300.0Kb)
PUBLISHER_POLICY
Publisher Policy
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Terms of use
Metadata
Show full item recordAbstract
The demand for plasmid DNA (pDNA) is anticipated to increase significantly as DNA vaccines and non-viral gene therapies enter phase 3 clinical trials and are approved for use. This increased demand, along with renewed interest in pDNA as a therapeutic vector, has motivated research targeting the design of high-yield, cost-effective manufacturing processes. An important aspect of this research is engineering bacterial strains and plasmids that are specifically suited to the production of plasmid biopharmaceuticals. This review will survey recent innovations in strain and vector engineering that aim to improve plasmid stability, enhance product safety, increase yield, and facilitate downstream purification. While these innovations all seek to enhance pDNA production, they can vary in complexity from subtle alterations of the host genome or vector backbone to the investigation of non-traditional host strains for higher pDNA yields.
Date issued
2009-02Department
Massachusetts Institute of Technology. Department of Chemical EngineeringJournal
Applied Microbiology and Biotechnology
Publisher
Springer Berlin Heidelberg
Citation
D. Bower and K. Prather, “Engineering of bacterial strains and vectors for the production of plasmid DNA,” Applied Microbiology and Biotechnology, vol. 82, Apr. 2009, pp. 805-813.
Version: Author's final manuscript
ISSN
1432-0614
0175-7598
Keywords
gene therapy, strain engineering, Escherichia coli, DNA vaccines, plasmid DNA